Sheila Riazi1, Natalia Kraeva2, Philip M Hopkins3. 1. The Department of Anesthesia, University of Toronto, 323-200 Elizabeth St, Toronto, ON, M5G 2C4, Canada. sheila.riazi@uhn.ca. 2. The Department of Anesthesia, University of Toronto, 323-200 Elizabeth St, Toronto, ON, M5G 2C4, Canada. 3. Department of Anaesthesia, University of Leeds, Leeds, United Kingdom.
Abstract
PURPOSE: This continuing professional development module aims to prepare anesthesiologists for the timely recognition and management of a malignant hyperthermia (MH) reaction, which is crucial for averting its life-threatening complications and ultimately for the patient's survival. PRINCIPAL FINDINGS: Malignant hyperthermia is a genetic disorder of skeletal muscle cells affecting myoplasmic calcium homeostasis. It can present with nonspecific signs of a hypermetabolic reaction, which can be fatal if treatment, including administration of dantrolene sodium, is not implemented promptly. Rapid evaluation and rejection of alternative diagnoses can lead to a prompt diagnosis and treatment and therefore will significantly reduce the complications, including renal failure, cardiac dysfunction, disseminated intravascular coagulation, and death. After the reaction, patients should be observed for a minimum of 24 hr because of the possibility of recrudescence. As it is a genetic condition, survivors and their family members should be referred to a specialized MH centre for further testing and counselling. CONCLUSIONS: The risk of dying from MH has increased over the past few years. A knowledgeable anesthesiologist who is diligent and attentive can recognize signs of an impending MH reaction and treat promptly to avoid complications of this deadly condition.
PURPOSE: This continuing professional development module aims to prepare anesthesiologists for the timely recognition and management of a malignant hyperthermia (MH) reaction, which is crucial for averting its life-threatening complications and ultimately for the patient's survival. PRINCIPAL FINDINGS:Malignant hyperthermia is a genetic disorder of skeletal muscle cells affecting myoplasmic calcium homeostasis. It can present with nonspecific signs of a hypermetabolic reaction, which can be fatal if treatment, including administration of dantrolene sodium, is not implemented promptly. Rapid evaluation and rejection of alternative diagnoses can lead to a prompt diagnosis and treatment and therefore will significantly reduce the complications, including renal failure, cardiac dysfunction, disseminated intravascular coagulation, and death. After the reaction, patients should be observed for a minimum of 24 hr because of the possibility of recrudescence. As it is a genetic condition, survivors and their family members should be referred to a specialized MH centre for further testing and counselling. CONCLUSIONS: The risk of dying from MH has increased over the past few years. A knowledgeable anesthesiologist who is diligent and attentive can recognize signs of an impending MH reaction and treat promptly to avoid complications of this deadly condition.
Authors: Philip M Jones; Britney N Allen; Richard A Cherry; Luc Dubois; Kelly N Vogt; Salimah Z Shariff; Krista M Bray Jenkyn; Sheila Riazi; Duminda N Wijeysundera Journal: Can J Anaesth Date: 2018-11-12 Impact factor: 5.063
Authors: Lydia D Hellwig; Clesson Turner; Teri A Manolio; Mark Haigney; Cynthia A James; Brittney Murray; Dale F Szpisjak; Sheila Muldoon; Juvianee Estrada-Veras; Alyson Krokosky; Mauricio J De Castro Journal: Mol Genet Genomic Med Date: 2018-11-10 Impact factor: 2.183
Authors: Heinz Jungbluth; Nicol C Voermans; Luuk R van den Bersselaar; Marc M J Snoeck; Madelief Gubbels; Sheila Riazi; Erik-Jan Kamsteeg Journal: Pract Neurol Date: 2020-10-27